A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)

Trial Identifier: D3614C00007
Sponsor:AstraZeneca
Collaborator:
Quotient Sciences Ltd
NCTID:NCT05419401
Start Date:April 2022
Primary Completion Date: July 2022
Study Completion Date: July 2022
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

LanguageDescription
English Version
English (UK) Translation

Trial Locations

CountryLocation
GB Ruddington, GB, NG11 6JS